Google Übersetzer
Cardiff Oncology Inc
About
Cardiff Oncology Inc (NASDAQ:CRDF) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 27 2026
Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity
Apr 17 2026
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting
Apr 9 2026
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth
Mar 20 2026
Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer
Mar 19 2026
Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting
Recent Videos
Cardiff Oncology Positive Update from its Randomized Phase 2 Trial of Onvansertib | Jan 27, 2026
Jan 28, 2026
CRDF Stock: Dips on Positive Randomized Phase 2 Results
Jan 27, 2026
27_01_26 Noticias de acciones biotecnológicas. Resumen diario. #Español #Shorts #diario $XBI
Jan 27, 2026
01_27_26 Biotech Stock News. Daily Recap. #English #Shorts $XBI #trading #biotechnews #dailynews
Jan 27, 2026
Financials
Revenue
$593 K
Market Cap
$108.02 M
EPS
-0.69
